Abstract
Aldose reductase enzyme (ALR2) of the polyol metabolic pathway, apart from its role as detoxifying enzyme towards toxic aldehydes, osmoregulator in the kidney and regulator of sperm maturation, was first found to be implicated in the etiology of the long term diabetic complications. However, to date, emerging reports have suggested that under normal glucose concentration, ALR2 may be up-regulated by factors other than hyperglycemia and therefore be involved also in other pathological processes that have become major threats to human health in the 21st century. Such pathologies are a number of cardiac disorders, inflammation, mood disorders, renal insufficiency and ovarian abnormalities. In addition, ALR2 was found to be over-expressed in different human cancers such as liver, breast, ovarian, cervical and rectal cancers. Although several aldose reductase inhibitors (ARIs) have progressed to the clinical level, only one is currently on the market. Thus, attention is currently targeted to discover ARIs of distinct chemical structures, being neither hydantoin nor carboxylic acid derivatives. The present review focuses on the molecular mechanisms by which ALR2 is implicated in a number of pathologies, on various aspects concerning its catalytic mechanism and its active site, and on the main classes of ARIs that have been developed to date, as well as on reported (quantitive) structure-activity relationships. The presented data aim to support the notion that ARIs are of pharmacotherapeutic interest for the pharmaceutical community and highlight essential aspects for the development of efficient and potent ARIs.
Keywords: Aldose reductase enzyme and aldose reductase inhibitors, long-term diabetic complications, cardiovascular disorders, inflammation, mood disorders, renal insufficiency, ovarian abnormalities, cancer
Current Medicinal Chemistry
Title: Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century
Volume: 16 Issue: 6
Author(s): Polyxeni Alexiou, Kyriaki Pegklidou, Maria Chatzopoulou, Ioannis Nicolaou and Vassilis J. Demopoulos
Affiliation:
Keywords: Aldose reductase enzyme and aldose reductase inhibitors, long-term diabetic complications, cardiovascular disorders, inflammation, mood disorders, renal insufficiency, ovarian abnormalities, cancer
Abstract: Aldose reductase enzyme (ALR2) of the polyol metabolic pathway, apart from its role as detoxifying enzyme towards toxic aldehydes, osmoregulator in the kidney and regulator of sperm maturation, was first found to be implicated in the etiology of the long term diabetic complications. However, to date, emerging reports have suggested that under normal glucose concentration, ALR2 may be up-regulated by factors other than hyperglycemia and therefore be involved also in other pathological processes that have become major threats to human health in the 21st century. Such pathologies are a number of cardiac disorders, inflammation, mood disorders, renal insufficiency and ovarian abnormalities. In addition, ALR2 was found to be over-expressed in different human cancers such as liver, breast, ovarian, cervical and rectal cancers. Although several aldose reductase inhibitors (ARIs) have progressed to the clinical level, only one is currently on the market. Thus, attention is currently targeted to discover ARIs of distinct chemical structures, being neither hydantoin nor carboxylic acid derivatives. The present review focuses on the molecular mechanisms by which ALR2 is implicated in a number of pathologies, on various aspects concerning its catalytic mechanism and its active site, and on the main classes of ARIs that have been developed to date, as well as on reported (quantitive) structure-activity relationships. The presented data aim to support the notion that ARIs are of pharmacotherapeutic interest for the pharmaceutical community and highlight essential aspects for the development of efficient and potent ARIs.
Export Options
About this article
Cite this article as:
Alexiou Polyxeni, Pegklidou Kyriaki, Chatzopoulou Maria, Nicolaou Ioannis and Demopoulos J. Vassilis, Aldose Reductase Enzyme and its Implication to Major Health Problems of the 21st Century, Current Medicinal Chemistry 2009; 16 (6) . https://dx.doi.org/10.2174/092986709787458362
DOI https://dx.doi.org/10.2174/092986709787458362 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Approaches to the treatment of chronic inflammation
Chronic inflammation is a hallmark of numerous diseases, significantly impacting global health. Although chronic inflammation is a hot topic, not much has been written about approaches to its treatment. This thematic issue aims to showcase the latest advancements in chronic inflammation treatment and foster discussion on future directions in this ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Female Sexual Dysfunction: Therapeutic Options and Experimental Challenges
Cardiovascular & Hematological Agents in Medicinal Chemistry Therapeutic Interventions in the Glyc(oxid)ation Pathway
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Modelling and Treating Amyotrophic Lateral Sclerosis through Induced- Pluripotent Stem Cells Technology
Current Stem Cell Research & Therapy Nutraceuticals against Neurodegeneration: A Mechanistic Insight
Current Neuropharmacology D-Serine Regulation: A Possible Therapeutic Approach for Central Nervous Diseases and Chronic Pain
Mini-Reviews in Medicinal Chemistry Antidiabetic Medicinal Plants as a Source of Alpha Glucosidase Inhibitors
Current Diabetes Reviews Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews The Potential Roles of Metallothionein as a Therapeutic Target for Cerebral Ischemia and Retinal Diseases
Current Pharmaceutical Biotechnology Immunotherapy-Based Strategies for the Treatment of Autoimmune Diabetes: Searching for the Cure
Current Pharmaceutical Design Clinical Applications of Myostatin Inhibitors for Neuromuscular Diseases
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Isoprostanes as Biomarkers and Mediators of Oxidative Injury in Infant and Adult Central Nervous System Diseases
Current Neurovascular Research Can Trehalose Prevent Neurodegeneration? Insights from Experimental Studies
Current Drug Targets Editorial [Hot Topic: Role of Oxidative-Nitrostative Stress and Poly(ADP-ribose) Polymerase in Cardiovascular Pathophysiology (Guest Editor: Pal Pacher)]
Current Vascular Pharmacology Magnetic Resonance-Based Metabolomics for Understanding Neurological Disorders: Current Status and Statistical Considerations
Current Metabolomics Stem Cell Therapies for the Lysosomal Storage Diseases – the Quintessential Neurodegenerative Diseases
Current Stem Cell Research & Therapy Neurotoxicity of Insecticides
Current Medicinal Chemistry Pharmacoproteomics Applications for Drug Target Discovery in CNS Disorders
Current Pharmacogenomics and Personalized Medicine Special Issue on Stem Cells: An Introduction from the Guest Editor
Current Neurovascular Research Patents on Therapeutic and Cosmetic Applications of Bioactives of Crocus Sativus L. and their Production through Synthetic Biology Methods: A Review
Recent Patents on Biotechnology Cation-Responsive MRI Contrast Agents Based on Gadolinium(III)
Current Inorganic Chemistry (Discontinued)